Med. praxi. 2014;11(5):200-203

Some diagnostic aspects of bronchial asthma

MUDr.Irena Krčmová, CSc., MUDr.Jakub Novosad, Ph.D.
Ústav klinické imunologie a alergologie
Univerzita Karlova v Praze, Lékařská fakulta a Fakultní nemocnice Hradec Králové

Individual asthma phenotypes are characterized by a different type of bronchial inflammation and present with distinct clinical features,

a different response to anti-inflammatory pharmacotherapy, and a different course and prognosis. The combination of current classifications

(severity, type of mucosal inflammation, and control achievement) provides a relatively precise presentation of the disease

and prognosis in an asthma sufferer. The diagnosis includes the degree of breathing disorder, reversibility of bronchial obstruction,

exhaled nitric oxide testing prior to treatment (or during its course), and triggers of asthma attacks. The diagnosis is supplemented by

complicating comorbidities. This is not a definitive text, but a dynamic description of the disease. Bronchomotor tests linked to FeNO

testing have separated a group of patients that exhibit symptoms of both asthma and chronic obstructive pulmonary disease. Hence,

the term "overlap syndrome" (an overlap of COPD genotype with asthma) or the acronym ACOS (asthma-chronic obstructive pulmonary

disease overlap syndrome) are encountered.

Keywords: bronchial asthma, diagnosis, classification, ACOS

Published: September 10, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krčmová I, Novosad J. Some diagnostic aspects of bronchial asthma. Med. praxi. 2014;11(5):200-203.
Download citation

References

  1. Salajka F, Kašák V, Krčmová I, Konštacký S. Asthma bronchiale. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. Centrum doporučených postupů pro praktické lékaře. Novelizace 2013.
  2. Vondra V, Malý M, Vondrová, I. Úmrtnost na astma a chronickou obstrukční plicní nemoc (CHOPN) v r. 2009 v České a Slovenské republice, Anglii a Walesu. Alergie 2011; 1: 16-18.
  3. Global strategy for astma management and prevention updated 2014: Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO. NIH Publication No.02-3659, updated 2014 and available on www.ginasthma.org.
  4. Krčmová I, Novosad J. Bronchiální astma - praktické aspekty. Interní Med 2010; 12(4): 196-199.
  5. Doporučený postup diagnostiky a léčby astmatu (2013), www.pneumologie.cz.
  6. Chládková J. Současný pohled na průduškové astma u dětí. Postgraduál Med 2012; 2: 129.
  7. Pohunek P. Dětské astma - čas pro změnu. Alergie 2008; Suppl. 1: 27-31.
  8. Anderson SD, Charlton B, Weiler JM, et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009; 10: 4-10. Go to original source... Go to PubMed...
  9. Anderson SD, Brannan JD. Bronchial provocation testing: the future. Curr Opin Allergy Clin Immunol 2011; 1: 46-52. Go to original source... Go to PubMed...
  10. Brannan JD, Porsbjerg C, Anderson SD. Inhaled mannitol as a test for bronchialhyper-responsiveness. Expert Rev Respir Med 2009; 3: 457-468. Go to original source... Go to PubMed...
  11. Sue-Chu M, Brannan JD, Anderson SD et al. Airway hyperresponsiveness to methacholine, adenosine5-monophosphate, mannito, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross country skiers. Brit J Sports Med 2010; 44: 827-832. Go to original source... Go to PubMed...
  12. Balzer S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011; 183: 299-309. Go to original source... Go to PubMed...
  13. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117: 1277-1284. Go to original source... Go to PubMed...
  14. Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflam Res 2009; 58: 631-638. Go to original source... Go to PubMed...
  15. Raed A, Dweik P, Boggs B, et al. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. Am J Respit Crit Care Med 2011; 184: 602-615. Go to original source... Go to PubMed...
  16. Čáp P. Některé diagnostické aspekty astmatu dospělých. Postgraduál Med 2012; 2: 137.
  17. Čáp P, Brezina M. Stanovení vydechovaného oxidu dusnatého u astmatu. Stud Pneumol Pthiseol 2007; 67: 63-67.
  18. Consensus Statement on the Use of Fractional Exhaled Nitric Oxide (FENO) in the Cinical Management of astma. National Jewish Health, December 2009, Denver. http://www.njhealth.org.
  19. Louie S, Zeki AA, Schivo M, Chan AL, Yoneda KY, Avdalovic M, Morrissey BM, Albertson TE. The Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome. Rev Clin Pharmacol 2013; 6(2): 197-219. Go to original source... Go to PubMed...
  20. Holgate S, Bisgaard H, Bjermer L, et al. The Brussels Declaration: the need for change in asthma management. Eur Respir J 2008; 32: 1433-1442. Go to original source... Go to PubMed...
  21. Taylor DR et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545-554. Go to original source... Go to PubMed...
  22. Teřl M. Pohled na astma prizmatem eozinofilie a alergie: návrh diagnostické klasifikace. Alergie 2009; 11(4): 247-255.
  23. Kašák V. Klinický význam konceptu tíže a kontroly astmatu. Farmakoterapie 2009; 5: 47-53.
  24. Kašák V. Novinky v léčbě astmatu. Postgraduál Med 2011; 6: 627-634.
  25. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162: 1403-1406. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.